Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

Journal of Experimental Medicine

Volumn 205, Issue 6, 2008, Pages 1317-1329

  Hömig Hölzel, Cornelia ^a,g   Hojer, Caroline ^a   Rastelli, Julia ^a,h   Casola, Stefano ^b,f   Strobl, Lothar J ^a   Müller, Werner ^c   Quintanilla Martinez, Leticia ^d   Gewies, Andreas ^e   Ruland, Jürgen ^e   Rajewsky, Klaus ^b   Zimber Strobl, Ursula ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CHIMERIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; IMMUNE RESPONSE; INCIDENCE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL;

ANIMALS; ANTIGENS, CD40; B-LYMPHOCYTES; CROSSES, GENETIC; GERMINAL CENTER; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOMA; LYMPHOMA, B-CELL; MICE; MICE, TRANSGENIC; NF-KAPPA B; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES; TNF RECEPTOR-ASSOCIATED FACTOR 2;

EID: 45149086054     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20080238     Document Type: Article

References (48)

1. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67:2-17.
2. DiSanto, J.P., J.Y. Bonnefoy, J.F. Gauchat, A. Fischer, and G. de Saint Basile. 1993. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature. 361:541-543.
3. Korthauer, U., D. Graf, H.W. Mages, F. Briere, M. Padayachee, S. Malcolm, A.G. Ugazio, L.D. Notarangelo, R.J. Levinsky, and R.A. Kroczek. 1993. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature. 361:539-541.
4. Kawabe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity. 1:167-178.
5. Xu, J., T.M. Foy, J.D. Laman, E.A. Elliott, J.J. Dunn, T.J. Waldschmidt, J. Elsemore, R.J. Noelle, and R.A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity. 1:423-431.
6. Grammer, A.C., and P.E. Lipsky. 2000. CD40-mediated regulation of immune responses by TRAF-dependent and TRAF-independent signaling mechanisms. Adv. Immunol. 76:61-178.
7. Hostager, B.S., I.M. Catlett, and G.A. Bishop. 2000. Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J. Biol. Chem. 275:15392-15398.
8. Hanissian, S.H., and R.S. Geha. 1997. Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells. Immunity. 6:379-387.
9. Craxton, A., G. Shu, J.D. Graves, J. Saklatvala, E.G. Krebs, and E.A. Clark. 1998. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J. Immunol. 161:3225-3236.
10. Li, Y.Y., M. Baccam, S.B. Waters, J.E. Pessin, G.A. Bishop, and G.A. Koretzky. 1996. CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells. J. Immunol. 157:1440-1447.
11. Sutherland, C.L., A.W. Heath, S.L. Pelech, P.R. Young, and M.R. Gold. 1996. Differential activation of the ERK, JNK, and p38 mitogen-activated protein kinases by CD40 and the B cell antigen receptor. J. Immunol. 157:3381-3390.
12. Berberich, I., G.L. Shu, and E.A. Clark. 1994. Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J. Immunol. 153:4357-4366.
13. Coope, H.J., P.G. Atkinson, B. Huhse, M. Belich, J. Janzen, M.J. Holman, G.G. Klaus, L.H. Johnston, and S.C. Ley. 2002. CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J. 21:5375-5385.
14. Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25:280-288.
15. Bonizzi, G., M. Bebien, D.C. Otero, K.E. Johnson-Vroom, Y. Cao, D. Vu, A.G. Jegga, B.J. Aronow, G. Ghosh, R.C. Rickert, and M. Karin. 2004. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 23:4202-4210.
16. Dejardin, E., N.M. Droin, M. Delhase, E. Haas, Y. Cao, C. Makris, Z.W. Li, M. Karin, C.F. Ware, and D.R. Green. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity. 17:525-535.
17. Derudder, E., E. Dejardin, L.L. Pritchard, D.R. Green, M. Korner, and V. Baud. 2003. RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J. Biol. Chem. 278:23278-23284.
18. Eliopoulos, A.G., and L.S. Young. 2004. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4:360-367.
19. Baxendale, A.J., C.W. Dawson, S.E. Stewart, V. Mudaliar, G. Reynolds, J. Gordon, P.G. Murray, L.S. Young, and A.G. Eliopoulos. 2005. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene. 24:7913-7923.
20. Challa, A., A.G. Eliopoulos, M.J. Holder, A.S. Burguete, J.D. Pound, A. Chamba, G. Grafton, R.J. Armitage, C.D. Gregory, H. Martinez-Valdez, et al. 2002. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood. 99:3411-3418.
21. Furman, R.R., Z. Asgary, J.O. Mascarenhas, H.C. Liou, and E.J. Schattner. 2000. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164:2200-2206.
22. Pham, L.V., A.T. Tamayo, L.C. Yoshimura, P. Lo, N. Terry, P.S. Reid, and R.J. Ford. 2002. A CD40 signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity. 16:37-50.
23. Gires, O., U. Zimber-Strobl, R. Gonnella, M. Ueffing, G. Marschall, R. Zeidler, D. Pich, and W. Hammerschmidt. 1997. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16:6131-6140.
24. Hatzivassiliou, E., W.E. Miller, N. Raab-Traub, E. Kieff, and G. Mosialos. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160:1116-1121.
25. Yasui, T., M. Muraoka, Y. Takaoka-Shichijo, I. Ishida, N. Takegahara, J. Uchida, A. Kumanogoh, S. Suematsu, M. Suzuki, and H. Kikutani. 2002. Dissection of B cell differentiation during primary immune responses in mice with altered CD40 signals. Int. Immunol. 14:319-329.
26. Kraus, M., M.B. Alimzhanov, N. Rajewsky, and K. Rajewsky. 2004. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 117:787-800.
27. Rickert, R.C., J. Roes, and K. Rajewsky. 1997. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25:1317-1318.
28. Bennett, B.L., D.T. Sasaki, B.W. Murray, E.C. O ' Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, et al. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA. 98:13681-13686.
29. Favata, M.F., K.Y. Horiuchi, E.J. Manos, A.J. Daulerio, D.A. Stradley, W.S. Feeser, D.E. Van Dyk, W.J. Pitts, R.A. Earl, F. Hobbs, et al. 1998. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273:18623-18632.
30. Panagopoulos, D., P. Victoratos, M. Alexiou, G. Kollias, and G. Mosialos. 2004. Comparative analysis of signal transduction by CD40 and the Epstein-Barr virus oncoprotein LMP1 in vivo. J. Virol. 78:13253-13261.
31. Bangs, S.C., A.J. McMichael, and X.N. Xu. 2006. Bystander T cell activation - implications for HIV infection and other diseases. Trends Immunol. 27:518-524.
32. Ehl, S., J. Hombach, P. Aichele, H. Hengartner, and R.M. Zinkernagel. 1997. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J. Exp. Med. 185:1241-1251.
33. Koschella, M., D. Voehringer, and H. Pircher. 2004. CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells. J. Immunol. 172:4804-4811.
34. Taraban, V.Y., T.F. Rowley, and A. Al-Shamkhani. 2004. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J. Immunol. 173:6542-6546.
35. Morse, H.C. III, M.R. Anver, T.N. Fredrickson, D.C. Haines, A.W. Harris, N.L. Harris, E.S. Jaffe, S.C. Kogan, I.C. MacLennan, P.K. Pattengale, and J.M. Ward. 2002. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 100:246-258.
36. Vonderheide, R.H., J.P. Dutcher, J.E. Anderson, S.G. Eckhardt, K.F. Stephans, B. Razvillas, S. Garl, M.D. Butine, V.P. Perry, R.J. Armitage, et al. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19:3280-3287.
37. Fiumara, P., and A. Younes. 2001. CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies. Br. J. Haematol. 113:265-274.
38. Basak, S., H. Kim, J.D. Kearns, V. Tergaonkar, E. O ' Dea, S.L. Werner, C.A. Benedict, C.F. Ware, G. Ghosh, I.M. Verma, and A. Hoffmann. 2007. A fourth IkappaB protein within the NF-kappaB signaling module. Cell. 128:369-381.
39. Hoffmann, A., and D. Baltimore. 2006. Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 210:171-186.
40. Annunziata, C.M., R.E. Davis, Y. Demchenko, W. Bellamy, A. Gabrea, F. Zhan, G. Lenz, I. Hanamura, G. Wright, W. Xiao, et al. 2007. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 12:115-130.
41. Keats, J.J., R. Fonseca, M. Chesi, R. Schop, A. Baker, W.J. Chng, S. Van Wier, R. Tiedemann, C.X. Shi, M. Sebag, et al. 2007. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 12:131-144.
42. Horie, R., T. Watanabe, Y. Morishita, K. Ito, T. Ishida, Y. Kanegae, I. Saito, M. Higashihara, S. Mori, M.E. Kadin, and T. Watanabe. 2002. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene. 21:2493-2503.
43. McCubrey, J.A., L.S. Steelman, W.H. Chappell, S.L. Abrams, E.W. Wong, F. Chang, B. Lehmann, D.M. Terrian, M. Milella, A. Tafuri, et al. 2007. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta. 1773:1263-1284.
44. Zheng, B., P. Fiumara, Y.V. Li, G. Georgakis, V. Snell, M. Younes, J.N. Vauthey, A. Carbone, and A. Younes. 2003. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood. 102:1019-1027.
45. Soriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21:70-71.
46. Lakso, M., B. Sauer, B. Mosinger Jr., E.J. Lee, R.W. Manning, S.H. Yu, K.L. Mulder, and H. Westphal. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc. Natl. Acad. Sci. USA. 89:6232-6236.
47. Ruland, J., G.S. Duncan, A. Elia, I. del Barco Barrantes, L. Nguyen, S. Plyte, D.G. Millar, D. Bouchard, A. Wakeham, P.S. Ohashi, and T.W. Mak. 2001. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell. 104:33-42.
48. Ruland, J., G.S. Duncan, A. Wakeham, and T.W. Mak. 2003. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity. 19:749-758.